65th ASH Annual Meeting & Exposition: 703. Cellular Immunotherapies: Basic and Translational: Cellular Immunotherapy: Preclinical and Translational Insights

Symposia: Cellular Immunotherapies: Basic and Translational Oral and Poster Abstracts
Oral

Research, clinical trials, ALL, Lymphoid Leukemias, Translational Research, Lymphomas, non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Plasma Cell Disorders, Diseases, immunology, Therapies, Lymphoid Malignancies, Biological Processes

Room 6A (San Diego Convention Center)

Moderators:

Zinaida Good, PhD, and R. Leo Sakemura, MD, PhD, Mayo Clinic

Disclosures:

Good: Kite Pharma, a subsidiary of Gilead Sciences: Research Funding; 10x Genomics, Inc.: Other: In-kind reagents and technical support; Standard BioTools, Inc.: Honoraria, Speakers Bureau; Mubadala Ventures: Consultancy; Atheneum Partners: Consultancy; Alpha Sights: Consultancy. Sakemura: Janssen: Honoraria.

4:00 PM

349

Role of Cell Therapy Product Characteristics in Patient Response to TAK-940 (CD19(T2)28z1xx Chimeric Antigen Receptor (CAR) T): Biomarker Analyses from a Phase I Study in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Varsha Sundaresan¹^*, Brigitte Senechal²^*, Xiuyan Wang, PhD²^*, Shubhra Kashyap¹^*, Erica Tong¹^*, Adarsh Joshi¹^*, Ajeeta Dash¹^*, Leopold Sellner¹^*, Sharon Chen¹^*, Devin McAvoy, BS³^*, Kinga K Hosszu, PhD³^*, Devanjan S Sikder²^*, Isabelle Riviere¹^*, Michel Sadelain, MD PhD⁴, Jae H. Park, MD⁵ and Reshma Singh¹^*

¹Takeda Development Center Americas, Inc., Lexington, MA
²Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Pediatrics and Immune Discovery & Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Cellular Therapeutics Service, Memorial Sloan Kettering Cancer Center, New York, NY

4:15 PM

350

Development of a Phase 1 Study Evaluating the Activity of Modular CAR T for Multiple Myeloma (MCARTY) Targeting BCMA and CD19 for Improved Persistence

Lydia Sarah Hui Lee, MD PhD^1,2^*, Wen Chean Lim, PhD³^*, Catriona Mactier, MD⁴^*, Juliana Dias Alves Pinto⁵^*, Vitoria Pereira⁵^*, Mhairi Vaughan⁵^*, Louisa Green⁵^*, Evie Lewin⁵^*, John Garcia⁵^*, Giulia Agliardi, PhD⁵^*, Yashma Pathak⁶^*, Riaz Jannoo⁶^*, Leigh Wood²^*, Bilyana Popova, MSc⁷^*, Helen Holmes⁷^*, Simon Thomas, PhD³^*, Victoria Spanswick, PhD⁶^*, William Wilson⁷^*, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD⁸, Rakesh Popat²^*, Claire Roddie, MD, PhD^1,2^*, Kwee Yong^1,9 and Martin A. Pule, MD^1,3^*

¹Research Department of Haematology, University College London Cancer Institute, London, United Kingdom
²Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
³Autolus Therapeutics, London, United Kingdom
⁴University College London, London, United Kingdom
⁵Centre for Cell, Gene & Tissue Therapeutics, University College London Cancer Institute, London, United Kingdom
⁶UCL ECMC GCLP Facility, University College London Cancer Institute, London, United Kingdom
⁷Cancer Research UK & UCL Cancer Trials Centre, University College London Cancer Institute, London, United Kingdom
⁸Leeds Teaching Hospitals NHS Trust, Leeds Cancer Centre, Leeds, United Kingdom
⁹Department of Haematology, University College London, London, United Kingdom

4:30 PM

351

CXCR4 Enriched T Regulatory Cells Preferentially Home to Bone Marrow and Decrease Inflammation

Meixian Huang¹^*, Mi-Ae Lyu¹^*, Ke Zeng, MD¹^*, Tara Sadeghi²^*, Lucia Masarova, MD³, Christopher R. Flowers, MD, MS¹ and Simrit Parmar, MBBS¹

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Cellenkos Inc., Houston, TX
³Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

4:45 PM

352

Single-Cell Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission

Zhiliang Bai, PhD¹^*, Bing Feng, PhD²^*, Susan E. Mcclory, MD, PhD³, Caroline Diorio, MD³, Ziran Zhao, PhD⁴, Li Tang, PhD²^*, J. Joseph Melenhorst, PhD⁵, Carl June, MD⁶, Stephan Grupp, MD, PhD³ and Rong Fan, PhD¹^*

¹Department of Biomedical Engineering, Yale University, New Haven, CT
²Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
³Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
⁴Center for ImmunoTherapy & Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH
⁵Cell Therapy and Immuno-Engineering Program, Center for ImmunoTherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
⁶Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA

5:00 PM

353

Novel Cancer Immunotherapy Using Cell-Derived Membrane Vesicles Orchestrates Multimodal Antitumor Immunity

Yusuke Ito, MD, PhD¹^*, Seiichi Ohta, PhD²^* and Yuki Kagoya, MD, PhD¹^*

¹Keio University School of Medicine, Tokyo, Japan
²Institute of Engineering Innovation, The University of Tokyo, Tokyo, Japan

5:15 PM

354

Enhancing MHC-Independent T Cell Receptors Using Rational Protein Engineering

Jufang Chang¹^*, Jack Landmann²^*, Yangdon Tenzin¹^*, John Warrington³^*, Mehmet Emrah Selli, PhD¹^*, Tien-Ching Chang³^*, Michael Slade, MD, MSCI⁴, Deepesh Gupta, PhD³^* and Nathan Singh, MD¹

¹Washington University School of Medicine, Saint Louis, MO
²Washington University School of Medicine, St. Louis, MO
³Washington University, St Louis, MO
⁴Division of Oncology, Washington University School of Medicine, Saint Louis, MO

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.O2.6 703. Cellular Immunotherapies: Basic and Translational: Cellular Immunotherapy: Preclinical and Translational Insights